methyl 2-[4-[[4-[[4-[(Z)-3H-1,3-benzothiazol-2-ylidene(cyano)methyl]pyrimidin-2-yl]oxymethyl]phenyl]methyl]piperazin-1-yl]acetate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[4-[[4-[[4-[(Z)-3H-1,3-benzothiazol-2-ylidene(cyano)methyl]pyrimidin-2-yl]oxymethyl]phenyl]methyl]piperazin-1-yl]acetate
• 化学式: C₂₈H₂₈N₆O₃S
• 分子量: 528.6
• InChiKey: YDDICXAZRILLFV-HPNDGRJYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• Benzothiazole Formulations and Use Thereof
  申请人：Esposito Pierandrea

  公开号：US20080051397A1

  公开（公告）日：2008-02-28

  The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.

  本发明涉及含有苯并噻唑衍生物的大聚乙二醇甘油酯制剂。具体地，本发明涉及苯并噻唑硬脂酰大聚乙二醇制剂，其制备方法和用途。
• Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
  申请人：Gaillard Pascale

  公开号：US20050261304A1

  公开（公告）日：2005-11-24

  The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.

  本发明涉及哌嗪苯并噻唑衍生物，特别是用于治疗和/或预防脑缺血性疾病或中枢神经系统疾病。本发明还涉及其制备方法。
• BENZOTHIAZOLE FORMULATIONS AND USE THEREOF
  申请人：ARES TRADING S.A.

  公开号：EP1812072A2

  公开（公告）日：2007-08-01
• Benzothiazole derivatives for the treatment of diabetes
  申请人：Gaillard Pascale

  公开号：US20070088017A1

  公开（公告）日：2007-04-19

  The present invention is related to the use of benzothiazole derivatives for the manufacture of a medicament for the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS) Formula (I). G is an unsubstituted or substituted pyrimidinyl group. L is an unsubstituted or substituted C 1 -C 6 -alkoxy, or an amino group, or an unsubstituted or a substituted 3-8 membered heterocycloalkyl, containing at least one heteroatom selected from N, O, S (e.g. a piperazine, a piperidine, a morpholine, a pyrrolidine). R 1 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, unsubstituted or substituted C 1 -C 6 -alkyl, unsubstituted or substituted C 2 -C 6 -alkenyl, unsubstituted or substituted C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy, unsubstituted or substituted aryl, halogen, cyano or hydroxy.
• US7314878B2
  申请人：——

  公开号：US7314878B2

  公开（公告）日：2008-01-01